logo
Plus   Neg
Share
Email

Meridian Bioscience Cuts FY19 Outlook, Suspends Dividend - Quick Facts

While reporting financial results for the second quarter, Meridian Bioscience, Inc. (VIVO) on Tuesday updated its earnings guidance for the full-year 2019, based on the pending acquisition of the business of GenePOC Inc.

For fiscal 2019, the company now expects the transaction to be dilutive to its previous full year adjusted earnings guidance range of $0.60 to $0.65 per share by about $0.10 to $0.12 per share, based on current purchase accounting estimates.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $0.66 per share for the year. Analysts' estimates typically exclude special items.

Further, the Board of Directors also suspended the company's quarterly cash dividend in connection with the announcement of its agreement to acquire the business of GenePOC Inc. and decision to allocate capital to related and other growth initiatives.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney Co. plans to lay off 28,000 theme park employees in U.S., as the coronavirus pandemic continues to affect its businesses. The layoff will affect about 67 percent of part-time employees. JPMorgan Chase & Co (JPM) agreed to pay a total of $920 million in penalty to settle U.S. investigations into the company's alleged manipulation of metal and treasuries markets. Elon Musk, the founder and CEO of Space Exploration Technologies, or SpaceX, said the aerospace company is planning to list its space internet venture, Starlink, after many years when revenue growth is smooth and predictable. In a tweet, Musk said, "We will probably IPO Starlink, but only several years in the future when revenue growth is smooth & predictable. Public market does *not* like erratic
Follow RTT